• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Tezepelumab reduced annual exacerbation rates in patients with severe asthma

byConstance Wu
June 1, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Subcutaneous tezepelumab treatment was shown to reduce the rate of annual asthma exacerbations in patients with severe asthma compared to the placebo group.

2. No significant differences in adverse events were found between the treatment and control groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In patients with severe asthma, thymic stromal lymphopoietin (TSLP) is a cytokine that exacerbates airway obstruction and increases airway inflammation. The cytokine can be blocked with the monoclonal antibody called tezepelumab. As such this trial, investigated the efficacy of tezepelumab to reduce the annual rate of asthma exacerbations. The study determined Tezepelumab treatment significantly reduced the annual rate of asthma exacerbations compared to the placebo treatment. Additionally, tezepelumab improved prebronchodilator 1-second forced expiratory volume (FEV1). No differences were found in both groups for the proportions of patients reporting adverse events with the most common event being upper respiratory tract infection. The study was limited by the strict inclusion criteria and the small number of adolescent patients included in the study. Nonetheless, the findings are still significant as the study provided evidence for the potential benefit of tezepelumab in severe asthma over multiple measures from exacerbation rates to lung function.

Click to read the study in NEJM

Relevant Reading: Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date

In-Depth [randomized controlled trial]: This randomized control trial across 297 sites in 18 countries enrolled 1,061 patients between the ages of 12 and 80 with severe asthma. Inclusion criteria were patients with diagnosed severe asthma for at least 12 months, an FEV1 of less than 80% of its predicted value, and a minimum of two asthma exacerbations required hospitalization. Patients who were smokers were not included in the study. The patients were randomized in a 1:1 ratio to receive tezepelumab or placebo, respectively, every four weeks for 52 weeks. The primary outcome was the annual asthma exacerbations rate. The study determined the annual asthma exacerbation rate was reduced to 0.93 (95% confidence interval [CI], 0.80 to 1.07) in the treatment group compared to 2.10 in the placebo group (95% CI, 1.84 to 2.39) (rate ratio, 0.44; 95% CI, 0.37 to 0.53; P<0.0001). Furthermore, patients receiving tezepelumab (0.23 liters) showed improvement in the prebronchodilator FEV1 compared to the placebo group (0.09 liters) (difference, 0.13 liters; 95% CI, 0.08 to 0.18; P<0.001. Similar proportions of both groups experienced adverse events with the most common severe event being nasopharyngitis, headache, and upper respiratory tract infections. Together, this study demonstrated the benefit of tezepelumab in improve symptom control and improve quality of life in patients with severe asthma.

RELATED REPORTS

Albuterol-budesonide combination efficacious for asthma exacerbation rescue

Phosphodiesterase 4 inhibitor BI 1015550 preserves lung function in pulmonary fibrosis patients

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: asthmapulmonarysevere asthmaTezepelumab
Previous Post

Increase in overdose-associated cardiac arrests during the COVID-19 pandemic

Next Post

Dexamethasone vs methylprednisolone high dose for COVID-19 pneumonia

RelatedReports

Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Emergency

Albuterol-budesonide combination efficacious for asthma exacerbation rescue

June 21, 2022
Interstitial lung abnormalities linked to greater risk of all-cause mortality
Chronic Disease

Phosphodiesterase 4 inhibitor BI 1015550 preserves lung function in pulmonary fibrosis patients

June 18, 2022
Masks for personal protection for SARS-CoV-2 infection
Chronic Disease

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

April 5, 2022
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Chronic Disease

Reliever-triggered inhaled glucocorticoid therapy in among Black and Latinx adults with asthma

March 9, 2022
Next Post
Significant number of wrong-patient errors in radiology reports

Dexamethasone vs methylprednisolone high dose for COVID-19 pneumonia

Soaring rates of peripheral artery disease, now over 200 million cases worldwide

Reduced-dose glucocorticoid adjunct non-inferior to high-dose glucocorticoid plus rituximab regimen for induction of disease remission in autoimmune vasculitis

Brain drain from sub-Saharan Africa to US worsening

Critically ill COVID-19 patients in Africa may have worse outcomes compared to global rates  

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.